St. Francis predicts X-Stop launch in mid-2005
This article was originally published in The Gray Sheet
Executive Summary
FDA-requested information to support approval for firm's X-Stop non-fusion lumbar device is "reasonable" and "readily available," President & CEO Kevin Sidow states. St. Francis will submit the requested data quickly, he says. In September, FDA's Orthopaedic & Rehabilitation Devices Panel voted 5-3 against approval of the device, which is meant to treat lumbar spinal stenosis, due to a lack of radiographic data proving reduction of stenosis-induced pressure on spinal nerve roots (1"The Gray Sheet" Sept. 6, 2004, p. 7). Sidow believes X-Stop is on track for a mid-2005 release in the U.S. Currently, the device is approved in Europe and Japan...
You may also be interested in...
FDA Panel Doubts Lumbar Fusion Alternative’s Imaging Data
St. Francis Medical should collect more detailed radiographic data of its X-Stop non-fusion lumbar device to prove reduction of stenosis-induced pressure on spinal nerve roots, FDA panelists urged Aug. 31
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.